U.S. Money Market Fund Holdings
U.S. Money Market Fund Holdings According to J.P. Morgan, the wall of cash may remain very high indefinitely, as defensive assets are delivering their weakest performance. Image: J.P. Morgan
U.S. Money Market Fund Holdings According to J.P. Morgan, the wall of cash may remain very high indefinitely, as defensive assets are delivering their weakest performance. Image: J.P. Morgan
Valuation – Average Forward P/E in Core PCE Inflation Ranges Since 1976 Historically, inflation generally had a negative impact on valuations when core PCE approached 2%, in the anticipation of rate hikes. Image: Goldman Sachs Global Investment Research
Consumer Demand for Gold China is the world’s largest consumer of gold, and India is the second largest consumer of gold. Image: Financial Times
Ownership of U.S. Corporate Bonds Around 28% of U.S. corporate bonds are held by non-U.S. investors. Image: BofA
Gold Inflows Since 2018 More retail investors are turning to gold investment. Image: BofA Global Research
Inflation – S&P 500 LTM Sales Growth vs. Core CPI Since 1970 Rising inflation tends to boost S&P 500 earnings. According to Goldman Sachs, a 100bp increase in average annual core CPI would lift the S&P 500 EPS to $170 in 2021. Image: Goldman Sachs Global Investment Research
Average S&P 500 Performance Around U.S. Presidential Elections Since 1972 Market volatility is expected to continue ahead of the U.S. presidential election. Image: Nordea and Macrobond
What Shape Is the Global Economic Downturn Most Likely to Take? A V-shaped global economic recovery seems unlikely. Image: Oxford Economics
GWIM Equity Flows – Buy the Dip? Time to buy the dip? BofA private clients have bought the dip in the past two weeks. Image: BofA Global Investment Strategy
Prediction for U.S. GDP Growth from Q42020 to Q42021 32 leading academic economists do not see significantly higher GDP growth under Donald Trump or Joe Biden, as long as the current control of Congress remains the same. Image: BofA
Coronavirus Vaccine in the U.S. Superforecasters see a 53% probability that 25 million doses of an FDA-approved COVID-19 vaccine will be available by March 2021 vs. 69% two weeks ago. Image: Goldman Sachs Global Investment Research